Folate-receptor-targeted delivery of docetaxel nanoparticles prepared by PLGA–PEG–folate conjugate
- 1 January 2008
- journal article
- Published by Taylor & Francis in Journal of Drug Targeting
- Vol. 16 (5) , 415-423
- https://doi.org/10.1080/10611860802088630
Abstract
For folate-receptor-targeted anticancer therapy, docetaxel (DTX) nanoparticles (NPs) were produced employing polylactide-co-glycolide-polyethylene glycol-folate (PLGA-PEG-FOL) conjugate. The FOL-conjugated di-block copolymer was synthesized by coupling the PLGA-PEG-NH(2) di-block copolymer with an activated folic acid. It was expected that FOL moieties were exposed on the micellar surface. The conjugates assisted in the formation of DTX NPs with an average size of 200 nm in diameter through an emulsification/solvent diffusion method. The FOL-targeted NPs showed a greater extent of intracellular uptake in FOL-receptor-positive cancer cells (SKOV3) in comparison with the non-targeted NPs, indicating that the FOL-receptor-mediated endocytosis mechanism could have a role in the cellular uptake of NPs. These results suggested that FOL-targeted DTX NPs could be a potentially useful delivery system for FOL-receptor-positive cancer cells.Keywords
This publication has 34 references indexed in Scilit:
- PLGA nanoparticles of different surface properties: Preparation and evaluation of their body distributionInternational Journal of Pharmaceutics, 2008
- Preparation of PLGA nanoparticles using TPGS in the spontaneous emulsification solvent diffusion methodJournal of Experimental Nanoscience, 2007
- Preparation and antibacterial activity evaluation of rifampicin-loaded poly lactide-co-glycolide nanoparticlesNanomedicine: Nanotechnology, Biology and Medicine, 2007
- Formulation of functionalized PLGA–PEG nanoparticles for in vivo targeted drug deliveryPublished by Elsevier ,2006
- Glucocorticoid Pathways in Chronic Obstructive Pulmonary Disease TherapyProceedings of the American Thoracic Society, 2005
- PLGA–mPEG nanoparticles of cisplatin: in vitro nanoparticle degradation, in vitro drug release and in vivo drug residence in blood propertiesJournal of Controlled Release, 2002
- The blood-brain barrier and oncology: new insights into function and modulationCancer Treatment Reviews, 2000
- Docetaxel (Taxotere®) a review of preclinical and clinical experience. Part IAnti-Cancer Drugs, 1995
- Rifampicin-carrying poly(D,L-Iactide) microspheres: Loading and releaseJournal of Biomaterials Science, Polymer Edition, 1995
- Studies on the in vivo disposition of adriamycin in human tumours which exhibit different responses to the drugBritish Journal of Cancer, 1986